Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Milestone Pharmaceuticals Inc.
Headquarters: Montreal, QC, Canada
Website: http://www.milestonepharma.com...
Year Founded: 2005
Status: Public
Industry Sector: HealthTechnology
CEO: Joseph G. Oliveto, MBA
Number Of Employees: 47
Enterprise Value: $57,508,151
PE Ratio: -2.26
Exchange/Ticker 1: NASDAQ:MIST
Exchange/Ticker 2: N/A
Latest Market Cap: $108,255,600
BioCentury | Mar 14, 2025
Data Byte
Ten PDUFA dates on FDA’s March agenda
Upcoming decisions include a label expansion for Alnylam’s Amvuttra, a new siRNA therapy for hemophilia, and more
BioCentury | Mar 28, 2023
Product Development
March 28 Quick Takes: Obesity data drive Viking shares to 52-week high
Plus: Arrivent raises $155M B round and updates from Sonoma, Regeneron, Intra-Cellular and more
BioCentury | Nov 16, 2022
Management Tracks
Bungay becomes CEO at Imophoron, Garzoni transitions to CSO
Plus: Tracy named CTO at Code, and updates from ConcertAI, Lucy, Trevi and more
BioCentury | Oct 18, 2022
Deals
Oct. 17 Quick Takes: Gilead, MacroGenics in deal for bispecific
Biogen’s ALS candidate delayed, plus updates from Oculis, Treeline, Minerva, Acrivon and more
BioCentury | Feb 17, 2022
Management Tracks
New leadership for Merck’s human health business
Plus new CEOs at Renibus and Indapta, updates from Milestone, Briacell and more
BioCentury | Jul 13, 2021
Emerging Company Profile
Ji Xing: building a CV pipeline for Chinese patients
Emerging Company Profile: Ji Xing to advance CV portfolio with $40M series B and Merck vet at the helm
BioCentury | Sep 1, 2020
Product Development
Aug. 31 Quick Takes: Mylan, Biocon launch cheaper insulin in U.S.; plus: AZ, bluebird, Lipocine, Amgen, AbbVie-Morphic, Polyphor-Fosun and Milestone
Mylan, Biocon launch long-acting insulin biosimilar in U.S. Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON; BSE:532523) launched Semglee insulin glargine in the U.S. at a wholesale acquisition
BioCentury | Mar 24, 2020
Product Development
Milestone says trial design trips up etripamil in tachycardia Phase III
BioCentury | Sep 13, 2019
Company News
Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more
BioCentury | May 9, 2019
Finance
Cortexyme’s first-day pop leads IPO quartet amid choppy market
How four IPOs helped push YTD tally from public market debuts well ahead of last year’s pace.
Items per page:
1 - 10 of 30